{"name":"POZEN","slug":"pozen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-07-01","label":"Ecotrin Phase 3 readout (Cardiovascular Diseases, Heart Failure)","drug":"Ecotrin","drugSlug":"ecotrin","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"EC Aspirin 325","genericName":"EC Aspirin 325","slug":"ec-aspirin-325","indication":"Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)","status":"marketed"},{"name":"Rescue Antacid","genericName":"Rescue Antacid","slug":"rescue-antacid","indication":"Heartburn and acid indigestion relief","status":"phase_3"},{"name":"aspirin and [NSAID]","genericName":"aspirin and [NSAID]","slug":"aspirin-and-nsaid","indication":"Acute pain management","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ecotrin","genericName":"Ecotrin","slug":"ecotrin","indication":"Other","status":"phase_1"},{"name":"PN 200","genericName":"PN 200","slug":"pn-200","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"PN 400 (VIMOVO)","genericName":"PN 400 (VIMOVO)","slug":"pn-400-vimovo","indication":"Treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis","status":"phase_3"},{"name":"celebrex","genericName":"celebrex","slug":"celebrex","indication":"Acute postoperative pain","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"PA32540","genericName":"PA32540","slug":"pa32540","indication":"Acute pain management (Phase 3 development)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Sumatriptan and Naproxen sodium","genericName":"Sumatriptan and Naproxen sodium","slug":"sumatriptan-and-naproxen-sodium","indication":"Acute migraine with or without aura","status":"marketed"}]}],"pipeline":[{"name":"EC Aspirin 325","genericName":"EC Aspirin 325","slug":"ec-aspirin-325","phase":"marketed","mechanism":"EC Aspirin 325 is an enteric-coated formulation of aspirin that inhibits platelet cyclooxygenase to prevent blood clots and reduce inflammation.","indications":["Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)","Reduction of cardiovascular risk in patients at risk for thrombotic events"],"catalyst":""},{"name":"Ecotrin","genericName":"Ecotrin","slug":"ecotrin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PA32540","genericName":"PA32540","slug":"pa32540","phase":"phase_3","mechanism":"PA32540 is a fixed-dose combination of acetaminophen and a nonsteroidal anti-inflammatory drug (NSAID) designed to provide enhanced pain relief with potentially improved gastrointestinal safety.","indications":["Acute pain management (Phase 3 development)"],"catalyst":""},{"name":"PN 200","genericName":"PN 200","slug":"pn-200","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PN 400 (VIMOVO)","genericName":"PN 400 (VIMOVO)","slug":"pn-400-vimovo","phase":"phase_3","mechanism":"VIMOVO combines the NSAID ibuprofen with the proton pump inhibitor omeprazole to reduce gastrointestinal side effects associated with NSAID therapy.","indications":["Treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis"],"catalyst":""},{"name":"Rescue Antacid","genericName":"Rescue Antacid","slug":"rescue-antacid","phase":"phase_3","mechanism":"Rescue Antacid neutralizes stomach acid to provide rapid relief from heartburn and acid indigestion.","indications":["Heartburn and acid indigestion relief"],"catalyst":""},{"name":"Sumatriptan and Naproxen sodium","genericName":"Sumatriptan and Naproxen sodium","slug":"sumatriptan-and-naproxen-sodium","phase":"marketed","mechanism":"Sumatriptan activates serotonin 5-HT1B/1D receptors to relieve migraine pain, while naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and provide additional analgesic effect.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"aspirin and [NSAID]","genericName":"aspirin and [NSAID]","slug":"aspirin-and-nsaid","phase":"marketed","mechanism":"This combination product pairs aspirin with an NSAID to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity through a fixed-dose formulation.","indications":["Acute pain management","Cardiovascular protection (aspirin component)"],"catalyst":""},{"name":"celebrex","genericName":"celebrex","slug":"celebrex","phase":"marketed","mechanism":"3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2","indications":["Acute postoperative pain","Ankylosing spondylitis","Dysmenorrhea","Juvenile rheumatoid arthritis","Osteoarthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQMnpodTZLNTVNYk00TEJmUzlmYmctXzlZS25FX09oQzR6ZDQzcG9MOU40RDZSZGphYm9HRFFXWUgzY1RlM2pKbVVpYy1RdmM1VklONkJvdFY4VkwxWkRVNDUxdEFndC1DY0pxMGREM0xoOUVkclF1RFY2RVJhUlpPeHNTTVJVTHRXLUJRMDFiSlQxWWM3S1UxUHlScmxnakhyOHJ1V01qTEN1S1dC?oc=5","date":"2016-10-04","type":"pipeline","source":"Fierce Pharma","summary":"Ambitious Aralez adds AstraZeneca’s Toprol to its expanding CV portfolio - Fierce Pharma","headline":"Ambitious Aralez adds AstraZeneca’s Toprol to its expanding CV portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOWExjN1dZRmJrNTlvZlpyNUNLR2t5SHNYYUtqTnJNeHYwdzJFSXVWZ2pkTk5GSWRWcHl0c2g1dUo2QlFHOWtTLVNsb25Tenp1Z2VUQ25nSlJJdmJDRzIxQkg5T2NYeXZ5R00yeFIwSElUUVZxaHlsVmd0VXpwR0lrTkx0RTl4TjExT21CRHY2TUJ0U3JWQzdWajhHdFdfVlNzTVB3OHRn?oc=5","date":"2016-09-08","type":"deal","source":"Fierce Pharma","summary":"With $25M-plus Aralez deal, Merck finds a buyer for abandoned clot-fighter Zontivity - Fierce Pharma","headline":"With $25M-plus Aralez deal, Merck finds a buyer for abandoned clot-fighter Zontivity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPbVkyZzNDZWE1d1VCMWtqb1Q3OHdkd2oydk0wUTZCWUNiT3BvOUJHc0dHYkpaclR0Rkd2Z3VRaU1WY0xpQXFtMnpyXzBSZkxBQV9Jbnhmc0pyWXZ3eVp1VE1IaW40ODlPbkg3U1hHbF82MzhoZWFQOEZLNTVIenppQkJ0eXZleDBKUGNIY1BmRjE3S1NwT2ZFN1ktMy13Zw?oc=5","date":"2015-06-10","type":"deal","source":"Contract Pharma","summary":"POZEN Acquires Tribute Pharmaceuticals in $146M Deal - Contract Pharma","headline":"POZEN Acquires Tribute Pharmaceuticals in $146M Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQNTNEWXBYeXNldFZyd1RNNXkyMXYxZ2RVTFRQa01HQkJCbjFCSFk5TkphSGVVMV9VdWt4c1VwNUZReUxlR3JuZ0otUFpkdnFONUFvQzU1eTFjYUtORjF1WlRKcW1NVElEVzhkZmxEeVRRS2pQNjdtWlFCOUMwVTEzS2NvOUJlR3BRTmpkVER5ZV93S2RBc3VzaXFCZ1dwUQ?oc=5","date":"2015-06-09","type":"pipeline","source":"The Irish Independent","summary":"Pharma giant Pozen to relocate to Ireland - The Irish Independent","headline":"Pharma giant Pozen to relocate to Ireland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNaG5OUGdmOGxwNVdWamk2RHZMMUxqaE1tc2Q3aHVXYk0zMnNsaENvSTBrNENIN2tqZFh3Z0dTM3pkSXo4WkZfVkw2UTNkNXRlU0lYeVZ2ZV9JNVJCVUczZXNVbDNTZWZ3WUMzbHZUVlZhVWU0U2xCRkFYQ1Y3WDllLTNhczNtTURlU1V3aFBCQTM?oc=5","date":"2015-06-08","type":"regulatory","source":"BioSpace","summary":"Pozen, Inc., Tribute to Unite Under Newly Formed Aralez Label - BioSpace","headline":"Pozen, Inc., Tribute to Unite Under Newly Formed Aralez Label","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQaUR4azhndm9IU3d5eWY1OFg5NnJvVnhaVGdJWlBGdWJJZWFTb2VTY05hckhFMDhBVllhNlJKcHRTMnFTeW9yazZYRjBHaVZkc19jTlJCdFRNMFFvX0FhN2tvS3FleXhPLXB5Q3hwOURvc19NMU1QMGVhMmpiVWlkOEhZOVk?oc=5","date":"2015-06-08","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Pozen Acquires Tribute Pharmaceuticals Canada - Genetic Engineering and Biotechnology News","headline":"Pozen Acquires Tribute Pharmaceuticals Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQaUhQTHIzS0RnX3FLdXFOYlFXbVdWeHE3VlBDVTRVMEZRb0VBR0JLZ3FTbXdvYUc4U1hWOGdQVHdCV0FQOWFuMG5iTFQzRGt1MFBKaVVRdHlWcUszMFQzdUg4enA0X3gxNDlKNXc4MFZvNXZ4Y3F4ZUVTQ25XNUs5THBpZExSLXo1cFd6ejRpLUtsR0Q4S2YyODlPSVpab3ZjUlR1WnFURQ?oc=5","date":"2015-06-08","type":"earnings","source":"The Business Journals","summary":"Chapel Hill's Pozen to move headquarters overseas with acquisition - The Business Journals","headline":"Chapel Hill's Pozen to move headquarters overseas with acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOcWltU0pxakRVQUl2RlFvUDVLYm85cFFYN0VSOS1kMDNnTVNGQUoyNXF4QmRfTlQxTjEwcWRmdVBCLUs2UW1wd3MyVTVtZWsxbnZzX1B0ZGR4NjQ0SzVCYkVNbDJCNDZiVjNLZU9lM3loQXhwNXQzQWtxUUIzdDNRMzdLTXZ1RGNhU0NBWXJCckl1cTVlTHRNWFo2YXhpNFpHNGx1TE05V0U5eG1tUkRRYXB6d2hXTDJ5SW5adXlKeTZ5OUJKOG1admtxTy1hUQ?oc=5","date":"2014-12-18","type":"regulatory","source":"The Pharma Letter","summary":"FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues - The Pharma Letter","headline":"FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOcXRURGh3bWtQTk5QWkhtcFgyb1c4NVpnTE12ell4VVVRN2xuQ3NTTWpJSXVpWFlSUUlrb0txUUhTd3JBTkxGSUVaUUhaLWpLMWdpUUNUZjVqNXFBbmgwVENNTlJsZmVRQnlmVGY5Wlk2eVdXVExTNWQ5WDJ0RTk0UTFrUlJqMFI1ZHJUdi1QQkdxT2NP?oc=5","date":"2014-07-02","type":"regulatory","source":"BioPharma Dive","summary":"Pozen takes aspirin/omeprazole combo back to FDA - BioPharma Dive","headline":"Pozen takes aspirin/omeprazole combo back to FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1NV2hzYTFXeDlLSHJ4cUplZEItcmVCN1MzRm5wV2ZLNlN5WU8wdFNWNktrT2RPVm4yazFzcGVkTks4NVpVWjdUTndfZlNZRTR4T1A4M3M3d0RiOUJQWVZNN2tMYkZuWmltOTJJYnpEZWJubXk3TkNUa0pnRlM?oc=5","date":"2013-11-20","type":"pipeline","source":"Pharmafile","summary":"AstraZeneca sells arthritis drug for $35 million - Pharmafile","headline":"AstraZeneca sells arthritis drug for $35 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSGtBUkJZNkVFdG9wV1pkU2FxSTFtYmdzWXdmclhuaktFcV9pOHdJNWRFMU13V0FzSGxvN0NvemxvcWNaZ245R2dfdlVTOFhZUWlUbkFqZ3ZqMVFuNldkUEQzenFvTE16SDJobmVranNGdUpGSVVBNi1LX2g4c1dUZDBGbXhfYmdsUmNjeTVTZXAwcU9N?oc=5","date":"2013-11-19","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Horizon Pharma Buys U.S. Rights to Vimovo from AstraZeneca - Genetic Engineering and Biotechnology News","headline":"Horizon Pharma Buys U.S. Rights to Vimovo from AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQaTNrb1FhOEdWQWNPdm1iWXkzUTVtR3VIdVl6T1Bpb3Fvbjh1WnZzQk1KX2VHMFlHSHF4UkdaZ1Uyei1GTDlzYlhzY3BVSjhYc1ZSWGpuOF93Z3B2ZEZlMVczUXpSLXcwWVdYX2ZuTkhvdFhjUUd0MU5vekxUb2tMeEUxcEhaaERmRXB0YWtUbXFNbW9CVVE?oc=5","date":"2008-04-16","type":"regulatory","source":"Contract Pharma","summary":"GSK, Pozen Gain FDA Approval for Migraine Drug - Contract Pharma","headline":"GSK, Pozen Gain FDA Approval for Migraine Drug","sentiment":"positive"}],"patents":[],"drugCount":9,"phaseCounts":{"marketed":4,"phase_1":2,"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}